Collegium Pharmaceutical Inc (NASDAQ:COLL) Director Michael Thomas Heffernan sold 25,000 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $11.26, for a total transaction of $281,500.00. Following the sale, the director now directly owns 132,069 shares of the company’s stock, valued at approximately $1,487,096.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Michael Thomas Heffernan also recently made the following trade(s):
- On Monday, June 17th, Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $11.37, for a total transaction of $284,250.00.
- On Wednesday, May 15th, Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $12.84, for a total transaction of $321,000.00.
Shares of COLL opened at $10.53 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.24 and a debt-to-equity ratio of 0.22. Collegium Pharmaceutical Inc has a 12-month low of $10.41 and a 12-month high of $21.20. The firm has a 50-day moving average price of $12.06.
COLL has been the subject of a number of research reports. Janney Montgomery Scott initiated coverage on shares of PLx Pharma in a report on Friday, April 12th. They set a “buy” rating for the company. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. BidaskClub lowered shares of Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research lowered shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Ballard Power Systems in a report on Friday, May 3rd. Three analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $26.17.
Institutional investors and hedge funds have recently made changes to their positions in the stock. MERIAN GLOBAL INVESTORS UK Ltd purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at about $26,000. First Quadrant L P CA purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at about $36,000. BNP Paribas Arbitrage SA grew its holdings in shares of Collegium Pharmaceutical by 67,855.6% in the first quarter. BNP Paribas Arbitrage SA now owns 6,116 shares of the specialty pharmaceutical company’s stock valued at $93,000 after purchasing an additional 6,107 shares during the period. Oregon Public Employees Retirement Fund purchased a new position in Collegium Pharmaceutical during the fourth quarter worth about $103,000. Finally, Virginia Retirement Systems ET AL purchased a new position in Collegium Pharmaceutical during the first quarter worth about $160,000. 94.83% of the stock is owned by hedge funds and other institutional investors.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Recommended Story: What does it mean to hold a stock in street name?
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.